Repositioning Candidate Details
| Candidate ID: | R0930 |
| Source ID: | DB06148 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Mianserin |
| Synonyms: | 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine; Mianserin |
| Molecular Formula: | C18H20N2 |
| SMILES: | CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21 |
| Structure: |
|
| DrugBank Description: | A tetracyclic compound with antidepressant effects. Mianserin was previously available internationally, however in most markets it has been phased out in favour of . |
| CAS Number: | 24219-97-4 |
| Molecular Weight: | 264.3648 |
| DrugBank Indication: | For the treatment of depression. |
| DrugBank Pharmacology: | Mianserin is a tetracyclic antidepressant that has antihistaminic and hypnosedative, but almost no anticholinergic, effect. It is a weak inhibitor of norepinephrine reuptake and strongly stimulates the release of norepinephrine. Interactions with serotonin receptors in the central nervous system have also been found. Its effect is usually noticeable after one to three weeks. Mianserin may cause drowsiness and hematological problems. |
| DrugBank MoA: | Mianserin's mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. |
| Targets: | Alpha-2A adrenergic receptor antagonist; 5-hydroxytryptamine receptor 2A antagonist; 5-hydroxytryptamine receptor 2C antagonist; Histamine H1 receptor antagonist; Sodium-dependent noradrenaline transporter inhibitor; Sodium-dependent serotonin transporter inhibitor; Histamine H4 receptor binder; 5-hydroxytryptamine receptor 1A blocker; Alpha-2C adrenergic receptor antagonist; 5-hydroxytryptamine receptor 2B binder; 5-hydroxytryptamine receptor 1F binder; Alpha-2B adrenergic receptor antagonist; Dopamine D3 receptor binder; Kappa-type opioid receptor agonist; Sodium-dependent dopamine transporter binder; 5-hydroxytryptamine receptor 7 antagonist; Dopamine D2 receptor antagonist; 5-hydroxytryptamine receptor 6 binder; Alpha-1 adrenergic receptors antagonist; D(1) dopamine receptor binder |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|